Oxygen-enhanced MRI MOLLI T1 mapping during chemoradiotherapy in anal squamous cell carcinoma

Emma Bluemke; Daniel Bulte; Ambre Bertrand; Ben George; Rosie Cooke; Kwun Ye Chu; Lisa Durrant; Vicky Goh; Clare Jacobs; Stasya Ng; Victoria Strauss; Maria Hawkins; Rebecca Muirhead

doi:10.1016/j.ctro.2020.03.001

Oxygen-enhanced MRI MOLLI T1 mapping during chemoradiotherapy in anal squamous cell carcinoma

Emma Bluemke, Daniel Bulte, Ambre Bertrand, Ben George, Rosie Cooke, Kwun Ye Chu, Lisa Durrant, Vicky Goh, Clare Jacobs, Stasya Ng, Victoria Strauss, Maria Hawkins, Rebecca Muirhead

Cancer Imaging

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Background and purpose: Oxygen-enhanced magnetic resonance imaging (MRI) and T1-mapping was used to explore its effectiveness as a prognostic imaging biomarker for chemoradiotherapy outcome in anal squamous cell carcinoma. Materials and methods: T2-weighted, T1 mapping, and oxygen-enhanced T1 maps were acquired before and after 8–10 fractions of chemoradiotherapy and examined whether the oxygen-enhanced MRI response relates to clinical outcome. Patient response to treatment was assessed 3 months following completion of chemoradiotherapy. A mean T1 was extracted from manually segmented tumour regions of interest and a paired two-tailed t-test was used to compare changes across the patient population. Regions of subcutaneous fat and muscle tissue were examined as control ROIs. Results: There was a significant increase in T1 of the tumour ROIs across patients following the 8–10 fractions of chemoradiotherapy (paired t-test, p < 0.001, n = 7). At baseline, prior to receiving chemoradiotherapy, there were no significant changes in T1 across patients from breathing oxygen (n = 9). In the post-chemoRT scans (8–10 fractions), there was a significant decrease in T1 of the tumour ROIs across patients when breathing 100% oxygen (paired t-test, p < 0.001, n = 8). Out of the 12 patients from which we successfully acquired a visit 1 T1-map, only 1 patient did not respond to treatment, therefore, we cannot correlate these results with clinical outcome. Conclusions: These clinical data demonstrate feasibility and potential for T1-mapping and oxygen enhanced T1-mapping to indicate perfusion or treatment response in tumours of this nature. These data show promise for future work with a larger cohort containing more non-responders, which would allow us to relate these measurements to clinical outcome.

Original language	English
Pages (from-to)	44-49
Number of pages	6
Journal	Clinical and Translational Radiation Oncology
Volume	22
DOIs	https://doi.org/10.1016/j.ctro.2020.03.001
Publication status	Published - May 2020

Keywords

Chemoradiotherapy
Hypoxia
MOLLI T1-Mapping
MRI
Oxygen Enhanced MRI (OE-MRI)
Tumour

Access to Document

10.1016/j.ctro.2020.03.001

https://www.ctro.science/article/S2405-6308(20)30014-8/pdfLicence: CC BY

Cite this

@article{8c708d54c5004d22baeffd6a49579f54,

title = "Oxygen-enhanced MRI MOLLI T1 mapping during chemoradiotherapy in anal squamous cell carcinoma",

abstract = "Background and purpose: Oxygen-enhanced magnetic resonance imaging (MRI) and T1-mapping was used to explore its effectiveness as a prognostic imaging biomarker for chemoradiotherapy outcome in anal squamous cell carcinoma. Materials and methods: T2-weighted, T1 mapping, and oxygen-enhanced T1 maps were acquired before and after 8–10 fractions of chemoradiotherapy and examined whether the oxygen-enhanced MRI response relates to clinical outcome. Patient response to treatment was assessed 3 months following completion of chemoradiotherapy. A mean T1 was extracted from manually segmented tumour regions of interest and a paired two-tailed t-test was used to compare changes across the patient population. Regions of subcutaneous fat and muscle tissue were examined as control ROIs. Results: There was a significant increase in T1 of the tumour ROIs across patients following the 8–10 fractions of chemoradiotherapy (paired t-test, p < 0.001, n = 7). At baseline, prior to receiving chemoradiotherapy, there were no significant changes in T1 across patients from breathing oxygen (n = 9). In the post-chemoRT scans (8–10 fractions), there was a significant decrease in T1 of the tumour ROIs across patients when breathing 100% oxygen (paired t-test, p < 0.001, n = 8). Out of the 12 patients from which we successfully acquired a visit 1 T1-map, only 1 patient did not respond to treatment, therefore, we cannot correlate these results with clinical outcome. Conclusions: These clinical data demonstrate feasibility and potential for T1-mapping and oxygen enhanced T1-mapping to indicate perfusion or treatment response in tumours of this nature. These data show promise for future work with a larger cohort containing more non-responders, which would allow us to relate these measurements to clinical outcome.",

keywords = "Chemoradiotherapy, Hypoxia, MOLLI T1-Mapping, MRI, Oxygen Enhanced MRI (OE-MRI), Tumour",

author = "Emma Bluemke and Daniel Bulte and Ambre Bertrand and Ben George and Rosie Cooke and Chu, {Kwun Ye} and Lisa Durrant and Vicky Goh and Clare Jacobs and Stasya Ng and Victoria Strauss and Maria Hawkins and Rebecca Muirhead",

year = "2020",

month = may,

doi = "10.1016/j.ctro.2020.03.001",

language = "English",

volume = "22",

pages = "44--49",

journal = "Clinical and Translational Radiation Oncology",

issn = "2405-6308",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Oxygen-enhanced MRI MOLLI T1 mapping during chemoradiotherapy in anal squamous cell carcinoma

AU - Bluemke, Emma

AU - Bulte, Daniel

AU - Bertrand, Ambre

AU - George, Ben

AU - Cooke, Rosie

AU - Chu, Kwun Ye

AU - Durrant, Lisa

AU - Goh, Vicky

AU - Jacobs, Clare

AU - Ng, Stasya

AU - Strauss, Victoria

AU - Hawkins, Maria

AU - Muirhead, Rebecca

PY - 2020/5

Y1 - 2020/5

N2 - Background and purpose: Oxygen-enhanced magnetic resonance imaging (MRI) and T1-mapping was used to explore its effectiveness as a prognostic imaging biomarker for chemoradiotherapy outcome in anal squamous cell carcinoma. Materials and methods: T2-weighted, T1 mapping, and oxygen-enhanced T1 maps were acquired before and after 8–10 fractions of chemoradiotherapy and examined whether the oxygen-enhanced MRI response relates to clinical outcome. Patient response to treatment was assessed 3 months following completion of chemoradiotherapy. A mean T1 was extracted from manually segmented tumour regions of interest and a paired two-tailed t-test was used to compare changes across the patient population. Regions of subcutaneous fat and muscle tissue were examined as control ROIs. Results: There was a significant increase in T1 of the tumour ROIs across patients following the 8–10 fractions of chemoradiotherapy (paired t-test, p < 0.001, n = 7). At baseline, prior to receiving chemoradiotherapy, there were no significant changes in T1 across patients from breathing oxygen (n = 9). In the post-chemoRT scans (8–10 fractions), there was a significant decrease in T1 of the tumour ROIs across patients when breathing 100% oxygen (paired t-test, p < 0.001, n = 8). Out of the 12 patients from which we successfully acquired a visit 1 T1-map, only 1 patient did not respond to treatment, therefore, we cannot correlate these results with clinical outcome. Conclusions: These clinical data demonstrate feasibility and potential for T1-mapping and oxygen enhanced T1-mapping to indicate perfusion or treatment response in tumours of this nature. These data show promise for future work with a larger cohort containing more non-responders, which would allow us to relate these measurements to clinical outcome.

AB - Background and purpose: Oxygen-enhanced magnetic resonance imaging (MRI) and T1-mapping was used to explore its effectiveness as a prognostic imaging biomarker for chemoradiotherapy outcome in anal squamous cell carcinoma. Materials and methods: T2-weighted, T1 mapping, and oxygen-enhanced T1 maps were acquired before and after 8–10 fractions of chemoradiotherapy and examined whether the oxygen-enhanced MRI response relates to clinical outcome. Patient response to treatment was assessed 3 months following completion of chemoradiotherapy. A mean T1 was extracted from manually segmented tumour regions of interest and a paired two-tailed t-test was used to compare changes across the patient population. Regions of subcutaneous fat and muscle tissue were examined as control ROIs. Results: There was a significant increase in T1 of the tumour ROIs across patients following the 8–10 fractions of chemoradiotherapy (paired t-test, p < 0.001, n = 7). At baseline, prior to receiving chemoradiotherapy, there were no significant changes in T1 across patients from breathing oxygen (n = 9). In the post-chemoRT scans (8–10 fractions), there was a significant decrease in T1 of the tumour ROIs across patients when breathing 100% oxygen (paired t-test, p < 0.001, n = 8). Out of the 12 patients from which we successfully acquired a visit 1 T1-map, only 1 patient did not respond to treatment, therefore, we cannot correlate these results with clinical outcome. Conclusions: These clinical data demonstrate feasibility and potential for T1-mapping and oxygen enhanced T1-mapping to indicate perfusion or treatment response in tumours of this nature. These data show promise for future work with a larger cohort containing more non-responders, which would allow us to relate these measurements to clinical outcome.

KW - Chemoradiotherapy

KW - Hypoxia

KW - MOLLI T1-Mapping

KW - MRI

KW - Oxygen Enhanced MRI (OE-MRI)

KW - Tumour

UR - http://www.scopus.com/inward/record.url?scp=85081965589&partnerID=8YFLogxK

U2 - 10.1016/j.ctro.2020.03.001

DO - 10.1016/j.ctro.2020.03.001

M3 - Article

SN - 2405-6308

VL - 22

SP - 44

EP - 49

JO - Clinical and Translational Radiation Oncology

JF - Clinical and Translational Radiation Oncology

ER -

Oxygen-enhanced MRI MOLLI T1 mapping during chemoradiotherapy in anal squamous cell carcinoma

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this